Effects of Intensive Uric Acid Lowering Therapy With RDEA3170 (Verinurad) and Febuxostat in Patients With Albuminuria
Phase of Trial: Phase II
Latest Information Update: 29 Aug 2018
At a glance
- Drugs Febuxostat (Primary) ; Verinurad (Primary)
- Indications Hyperuricaemia; Proteinuria; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 31 Aug 2018 Biomarkers information updated
- 21 Aug 2018 Status changed from active, no longer recruiting to completed.
- 04 Apr 2018 Planned End Date changed from 24 Aug 2018 to 13 Aug 2018.